Time filter

Source Type

Liaocheng, China

Objective To evaluate the efficacy and safety of ultrasound-guided transrectal ethanol injection for the treatment of benign prostatic hyperplasia (BPH) in patients with high-risk comorbidities. Methods Seventy patients with BPH who showed poor oral drug efficacy and were medically fragile or unwilling to undergo operative therapy were enrolled in the study. They received ultrasound-guided transrectal ethanol injection and were followed up at 1, 3, 6, 12, and 24 months post-treatment. Volume and pathology of the prostate were observed. International prostate symptom score, quality of life, maximum urinary flow rate (Qmax), and postvoid residual volume were determined. The clinical complications were also recorded. Results After 24 months of treatment, prostate volume, international prostate symptom score, quality of life score, and postvoid residual of patients were significantly reduced when compared with the pretreatment values (55.9 ± 16.7 vs 46.8 ± 8.1 mL, 29.3 ± 6.7 vs 9.8 ± 2.4 points, 5.3 ± 1.7 vs 1.9 ± 0.7 points, and 130.8 ± 71.5 vs 25.9 ± 12.0 mL, respectively, P <.05). Qmax significantly increased to 15.3 ± 3.2 mL/s than the pretreatment Qmax of 4.7 ± 3.1 mL/s (P =.001). Four of 36 patients who received a high dose of ethanol developed liquefaction necrosis and urinary tract injury (2 patients each). However, the subsequent 34 patients received a reduced dose of ethanol and had no complications. Conclusion The minimally invasive technique of ultrasound-guided transrectal ethanol injections showed good efficacy with few complications for the treatment of patients with BPH and other high-risk comorbidities. Source

Lv R.,Tumour Hospital of Liaocheng | Feng Q.-L.,Tumour Hospital of Liaocheng | Li Y.-J.,Tumour Hospital of Liaocheng | Xu Y.-J.,Tumour Hospital of Liaocheng | Jia X.-Q.,Tumour Hospital of Liaocheng
Journal of Practical Oncology | Year: 2013

To analyze the therapeutic effect of medical imaging-guided intratumoral injection of ethanol combined with microwave for the treatment of recurrent malignant schwannoma. Eight patients with recurrent malignant schwannoma who could not be re-resected were injected with ethanol intratumorally under CT or ultrasound and then combined with microwave ablation. The improved clinical symptoms after treatment, the local tumor control effect and the long-term efficacy were observed. After treatment, the clinical symptoms in 8 patients were improved by varying degrees. The Karnofsky score was raised from 67.52 ± 10.50 before treatment to 85.33 ± 14.32 (P=0.013). Enhanced CT scan showed no tumor enhancement and the volume was gradually reduced from (34.65 ± 9.27) cm3 before treatment to (24.51 ± 6.32) cm3 (P=0.011) after six-month follow-up. The overall follow-up was 24 to 62 months. Six cases were surviving and 2 died and no obvious treatment-related complications were discovered. Ethanol injection combined with microwave ablation for the treatment of malignant schwannoma shows minimal invasion, slight complications and significant local efficacy and can be used as a supplementary treatment for patients with recurrent malignant schwannoma. Source

Discover hidden collaborations